Highly Selective Red-Emitting Fluorescent Probe for Imaging Cancer Cells in Situ by Targeting Pim-1 Kinase
Source abstract
Abstract
Based on the fact that enzyme-targeting probes are highly sensitive and selective, a novel red-emitting probe ( NB-BF ) for Pim-1 kinase including three parts, fluorophore ( NB ), linker, and inhibitor ( BF ), has been designed for cancer optical imaging. In its free state, NB-BF is folded and the fluorescence quenched by PET between fluorophore and inhibitor both in PBS buffer and in normal cells. Significantly, it emitted strong red fluorescence in Pim-1 overexpressed cancer cells. The specificity of NB-BF for Pim-1 kinase was directly demonstrated by gene silencing analysis. Furthermore, it is the first time to know where Pim-1 kinase mainly distributes at mitochondria with Pearson’s correlation factor ( R r ) of 0.965 and to provide a fluorescent tool to verify the function of the Pim-1 kinase. More importantly, NB-BF was applied in tissue imaging and preferentially labeled tumors in vivo.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Cancer Mechanisms and Therapy · Peptidase Inhibition and Analysis · Synthesis and biological activity
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Fine Chemicals and ‡School of Pharmaceutical Science and Technology, Dalian University of Technology, Dalian, 116024, China
Funding
National Natural Science Foundation of China
References (43)
Show source-provided references
1. 10.1002/anie.20140549010.1002/anie.201405490 ↗
2. 10.3322/caac.2013810.3322/caac.20138 ↗
3. 10.1002/anie.20140230510.1002/anie.201402305 ↗
4. 10.1039/c4cc02878c10.1039/c4cc02878c ↗
5. 10.1002/anie.20131113310.1002/anie.201311133 ↗
6. 10.1016/j.cellimm.2011.10.01110.1016/j.cellimm.2011.10.011 ↗
7. 10.1016/j.bmcl.2010.03.06110.1016/j.bmcl.2010.03.061 ↗
8. 10.1158/1541-7786.MCR-05-000710.1158/1541-7786.MCR-05-0007 ↗
9. 10.1158/1535-7163.MCT-08-103710.1158/1535-7163.MCT-08-1037 ↗
10. 10.1002/pros.2006410.1002/pros.20064 ↗
11. 10.1016/j.mce.2012.10.02810.1016/j.mce.2012.10.028 ↗
12. Warnecke E. U. · Anticancer Res. · 2009 · 29 · 4451
13. 10.1158/1535-7163.MCT-06-039710.1158/1535-7163.MCT-06-0397 ↗
14. 10.1016/j.lfs.2010.12.00110.1016/j.lfs.2010.12.001 ↗
15. 10.1038/srep3807910.1038/srep38079 ↗
16. 10.2217/fon.10.10610.2217/fon.10.106 ↗
17. 10.1371/journal.pone.000257210.1371/journal.pone.0002572 ↗
18. 10.1002/pros.2029410.1002/pros.20294 ↗
19. 10.1074/jbc.M109.08725410.1074/jbc.M109.087254 ↗
20. Roh M. · Cancer. Res. · 2003 · 63 · 8079
21. 10.1046/j.1432-1327.2000.01585.x10.1046/j.1432-1327.2000.01585.x ↗
22. 10.1007/s00412-002-0192-610.1007/s00412-002-0192-6 ↗
23. 10.1016/j.molonc.2008.04.00110.1016/j.molonc.2008.04.001 ↗
24. 10.1073/pnas.091026110710.1073/pnas.0910261107 ↗
25. 10.1039/C6CS00908E10.1039/C6CS00908E ↗
26. 10.1126/scitranslmed.300282310.1126/scitranslmed.3002823 ↗
27. 10.1021/ja309346f10.1021/ja309346f ↗
28. 10.1016/j.biomaterials.2011.06.02410.1016/j.biomaterials.2011.06.024 ↗
29. 10.1007/s00464-013-3305-910.1007/s00464-013-3305-9 ↗
30. 10.1007/s00464-014-3423-z10.1007/s00464-014-3423-z ↗
31. 10.1021/ja405292210.1021/ja4052922 ↗
32. 10.1021/cb400698s10.1021/cb400698s ↗
33. 10.1039/C4CS00334A10.1039/C4CS00334A ↗
34. 10.1039/C4CC08915D10.1039/C4CC08915D ↗
35. 10.1021/ja408530810.1021/ja4085308 ↗
36. 10.1039/C7CC01798G10.1039/C7CC01798G ↗
37. 10.1021/ja405690510.1021/ja4056905 ↗
38. 10.1016/j.bmcl.2011.03.03010.1016/j.bmcl.2011.03.030 ↗
39. 10.1016/S1093-3263(02)00164-X10.1016/S1093-3263(02)00164-X ↗
40. 10.1002/prot.1056710.1002/prot.10567 ↗
41. 10.1021/jm049524q10.1021/jm049524q ↗
42. 10.1016/j.ejca.2008.06.04410.1016/j.ejca.2008.06.044 ↗
43. 10.1038/onc.2009.12410.1038/onc.2009.124 ↗